BMO Capital Initiates Coverage on Jazz Pharmaceuticals plc – Ordinary Shares to Outperform

BMO Capital Initiates Coverage on Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ). The shares have been rated Outperform. The rating by BMO Capital was issued on Jun 29, 2016.

In a different note, Goldman Sachs said it Initiates Coverage on Jazz Pharmaceuticals plc – Ordinary Shares, according to a research note issued on Jun 6, 2016. The shares have been rated ‘Buy’ by the firm. On Jun 2, 2016, SunTrust Robinson Humphrey said it Maintains its rating on Jazz Pharmaceuticals plc – Ordinary Shares. In the research note, the firm Raises the price-target to $200.00 per share. The shares have been rated ‘Buy’ by the firm. On May 11, 2016, Mizuho Securities said it Upgrades its rating on Jazz Pharmaceuticals plc – Ordinary Shares. The shares have been rated ‘Buy’ by the firm. On Apr 25, 2016, SunTrust Robinson Humphrey said it Upgrades its rating on Jazz Pharmaceuticals plc – Ordinary Shares. In the research note, the firm Raises the price-target to $164.00 per share. The shares have been rated ‘Buy’ by the firm.

Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) shares turned negative on Fridays trading session with the shares closing down -0.27 points or -0.19% at a volume of 5,89,531. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $143.79. The peak price level was also seen at $143.79 while the days lowest was $140.06. Finally the shares closed at $141.04. The 52-week high of the shares is $194.73 while the 52-week low is $108.5. According to the latest information available, the market cap of the company is $8,522 M.

Jazz Pharmaceuticals plc – Ordinary Shares(JAZZ) last announced its earnings results on May 10, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $336.01M. Analysts had an estimated revenue of $342.95M. Earnings per share were $2.26. Analysts had estimated an EPS of $2.35.

Several Insider Transactions has been reported to the SEC. On Jun 16, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $149.64 per share price.Also, On Jun 15, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 557 shares at $149.61 per share price.On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price, according to the Form-4 filing with the securities and exchange commission.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Jazz Pharmaceuticals plc - Ordinary Shares - Is it time to Sell?

Top Brokerage Firms are advising their investors on Jazz Pharmaceuticals plc - Ordinary Shares. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.